Shanghai Novamab Biopharmaceuticals Co., Ltd.
Monday, June 03, 2024
Company Presentation
Immunology
Company Presentation Theater 2
Novamab leverages an unparalleled single-domain antibody (sdAb) and unmet clinical needs oriented strategy to establish multiple innovative platforms while incubating competitively positioned first-in-class drugs since founded in 2017. With a robust R&D foundation over 6 years, Novamab has upgraded multiple platforms, including inhaled sdAb, synthetic cytokine surrogate, etc. These advancements encompass more than 10 drug candidates across various therapeutic areas, respiratory diseases, autoimmune diseases, ophthalmology, and oncology. Our flagship drug candidate, LQ036, the FIC inhaled sdAb neutralizing IL-4Rα for asthma and COPD treatment, is currently progressing phase 2 clinical development. Another promising candidate, LQ043H, the first inhaled sdAb neutralizing TSLP for asthma and COPD treatment, is slated to advance into phase 2 trials in 2024. Novamab is actively developing innovative drugs, while simultaneously seeking collaboration and commercial partnerships.
Company Website:
http://en.novamab.com/
Lead Product in Development:
Inhaled sdAb platform:
LQ036: Inhalable sdAb neutralizing IL-4Rα signaling for asthma and COPD, Phase II
LQ043H: Inhalable sdAb neutralizing TSLP signaling for asthma and COPD, Phase Ib/IIa
LQ059: Inhalable sdAb targeting Notch2 signaling for cystic fibrosis, Drug Discovery-PCC
Synthetic cytokine surrogate sdAb platform:
LQ060: sdAb-based biological agonist of IL-10Ra/Rb for autoimmune diseases, Drug Discovery-PCC
LQ058: sdAb-based biological agonist of IL-18R1/R2 for multiple cancers, Drug Discovery-PCC
Blood-Brain Barrier (BBB) penetrating TfR sdAb delivery platform:
LQ061: sdAb-based TfR1 and VEGF bispecific antibody for Glioblastoma, Drug Discovery-PCC
Long-acting sdAb platform:
LQ080: sdAb-based TL1A/IL-23 p19 bispecific antibody for inflammatory bowel diseases and Scleroderma-associated interstitial lung disease, Drug Discovery-PCC
LQ041: sdAb-based IL-5 antibody for eosinophil related inflammation, Drug Discovery-PCC
Others:
LQ015: VEGF neutralizing sdAb eyedrops for wAMD, Drug Discovery-PCC
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Company HQ City
Shanghai
Company HQ State
Shanghai
Company HQ Country
China
CEO/Top Company Official
Yakun Wan
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())